An optimized Box-Behnken design RP-HPLC method for the quantification of Umiclinidinium Bromide and Vilanterol Trifenate in inhalation powder
DOI:
https://doi.org/10.22456/2527-2616.138200Keywords:
Vilanterol Trifenate, Umiclinidinium Bromide, Quality by design, RP-HPLCAbstract
A liquid chromatographic method with enhanced efficacy has been proposed for the simultaneous quantification of Vilanterol Trifenate and Umiclinidinium Bromide in pharmaceutical formulation. This method is straightforward, sensitive, accurate, precise, and dependable. The RP-HPLC method's experimental parameters were multivariately optimized using the design of experiments (DoE). Mathematical models were created using three independent variables: the percentage of acetonitrile, the strength of the buffer, and the pH of the mobile phase. In order to examine the response surface methodology and the effects of these independent factors, a box-behnken design (BBD) was utilized. The optimized and forecasted data from the contour diagram utilized a mixture of acetonitrile (58.6% v/v) and phosphate buffer (12.6 mM) with a pH of 5.1. The flow rate was adjusted to 1 milliliter per minute and the analytical wavelength employed was 272 nm. The pharmaceuticals were successfully separated with high resolution in less than 6 minutes under ideal conditions, and the validation process was conducted in accordance with the requirements set by the International Council for Harmonisation (ICH). The findings indicated that the Quality by Design technique was effective in optimizing the RP-HPLC method for quantifying Vilanterol Trifenate and Umiclinidinium Bromide.
Downloads
References
Satoskar RS, Bhandarkar SD, Ainapure SS. Pharmacology and Pharmacotherapeutics. 6th ed, 2001, Mumbai, India.
Burger’s Medicinal Chemistry and drug discovery, 6 th edition, Wiley Interscience, New Jersey, 2007.
Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry, 11th edition, Lippincott Williams & Wilkins, New york, 2004.
Korolkovas, “Essentials of Medicinal Chemistry” 2nd edition, Wiley Interscience, New Jersey, 1988.
Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 9th edition, McGraw-Hill health professions division, New york, 1996.
Foye’s Principles of Medicinal Chemistry, 6th edition, Lippincott Williams & Wilkins, New york, 2008.
Kelleher DL, Mehta RS. Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol aone and in Combination: A Randomized Crossover Trial. PLOSOne.2012; 7(12): 507-16
Dumitrescu TP, Santos LL. A Novel Method for Studying the Pharmacokinetics of Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects. Clin Transl Sci. 2016; 9(4): 183–191.
Masimukku SK, Chintala R. Development and Validation of Spectrophotometric Methods for Simultaneous Estimation of Vilanterol and Fluticasone Furoate in Pharmaceutical Formulations. Asian J Pharm Clin Res.2017;10(4): 302-305.
Sindhu SD, Rani SS. Stability indicating RP-HPLC method development and validation for the simultaneous estimation of vilanterol and umeclidinium bromide in bulk and pharmaceutical dosage forms. World J Pharm Sci.2022; 10(01): 128- 135.
Rajesh G, Thejomoorthy K, Prasanna PS. New Stability Indicating High Performance Liquid Chromatography Method for Determination of Vilanterol and Umeclidinium Bromide in Bulk And Tablet Dosage Form. Eur J Biomed Pharm Sci. 2021; 6(8) :399-408.
Koppisetty BRB, Prasad PYR, Amgoth KMP, Yarraguntla SR, Dadi V, Tatapudi HK. Utility Of Quality by Design Approach In RP-HPLC Method Development for Quantification of Lamivudine and Effavirenz in Combination Formulation. Ankara Univ Eczacilik Fak Derg. 2023; 47: 625-636.
Group IEW, editor ICH Harmonized tripartite guideline. Pharmaceutical development Q8 (R2). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2009
ICH. Validation of Analytical Procedures: Text and Methodology Q2 (R1), International Conference on Harmonisation. Geneva: ICH; 2005
Downloads
Published
Versions
- 26-03-2026 (2)
- 19-07-2024 (1)
How to Cite
Issue
Section
License
Copyright (c) 2024 Drug Analytical Research

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Copyright holder of manuscripts published is Drug Analytical Research. Authors who publish with this journal are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Licensing:
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.





